Stay updated with breaking news from Alto investors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Robert W. Baird assumed coverage on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a report issued on Wednesday morning, MarketBeat reports. The firm issued a neutral rating and a $15.00 price target on the biopharmaceutical company’s stock. Several other brokerages have also recently commented on SAGE. Truist Financial reduced their target price on […] ....
Nevro (NYSE:NVRO) PT Lowered to $13.00 at Wells Fargo & Company themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price objective lowered by stock analysts at Canaccord Genuity Group from $21.00 to $17.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target indicates a potential upside of […] ....
Sage Therapeutics (NASDAQ:SAGE – Get Free Report) had its price target lowered by equities researchers at Mizuho from $20.00 to $18.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Mizuho’s price target would indicate a potential upside of […] ....
AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Partnrs in a research note issued to investors on Tuesday, Zacks.com reports. Leerink Partnrs also issued estimates for AnaptysBio’s Q1 2024 earnings at ($1.41) EPS, Q2 2024 earnings at ($1.44) EPS, Q3 2024 earnings at ($1.45) EPS, Q4 […] ....